Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 36 entries
View as:

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

Phase: N/A Priority: Normal
NCT ID: NCT03835884 Org: User:
Start: 06/24/19 End: 05/12/22 Due: 05/12/23

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Phase: N/A Priority: Normal
NCT ID: NCT03808688 Org: User:
Start: 12/27/18 End: 07/26/19 Due: 07/26/20

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02558374 Org: User:
Start: 09/30/15 End: 12/31/16 Due: 12/31/17

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02558400 Org: User:
Start: 09/18/15 End: 06/30/17 Due: 06/30/18

Ocular Hypotensive Efficacy of AR-102

Phase: N/A Priority: Normal
NCT ID: NCT00523250 Org: User:
Start: 09/30/07 End: 03/31/08 Due: 03/31/09

Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01997879 Org: User:
Start: 11/30/13 End: 11/30/13 Due: 11/30/14

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Phase: N/A Priority: Normal
NCT ID: NCT03739593 Org: User:
Start: 03/13/19 End: 07/09/20 Due: 07/09/21

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02207491 Org: User:
Start: 07/31/14 End: 03/31/15 Due: 03/31/16

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Phase: N/A Priority: Normal
NCT ID: NCT01528787 Org: User:
Start: 03/31/12 End: 07/31/12 Due: 07/31/13

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT03310580 Org: User:
Start: 11/15/17 End: 10/25/18 Due: 10/25/19

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

Phase: N/A Priority: Normal
NCT ID: NCT00902200 Org: User:
Start: 05/31/09 End: 09/30/09 Due: 09/30/10

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02207621 Org: User:
Start: 07/31/14 End: 03/31/16 Due: 03/31/17

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

Phase: N/A Priority: Normal
NCT ID: NCT01731002 Org: User:
Start: 11/30/12 End: 05/31/13 Due: 05/31/14

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Phase: N/A Priority: Normal
NCT ID: NCT03233308 Org: User:
Start: 10/20/17 End: 04/19/18 Due: 04/19/19

A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

Phase: N/A Priority: Normal
NCT ID: NCT01699464 Org: User:
Start: 10/31/12 End: 04/30/13 Due: 04/30/14

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Phase: N/A Priority: Normal
NCT ID: NCT02057575 Org: User:
Start: 01/31/14 End: 06/30/14 Due: 06/30/15

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

Phase: N/A Priority: Normal
NCT ID: NCT01474135 Org: User:
Start: 12/31/11 End: 04/30/12 Due: 04/30/13

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Phase: N/A Priority: Normal
NCT ID: NCT01789736 Org: User:
Start: 02/28/13 End: 06/30/13 Due: 06/30/14

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02246764 Org: User:
Start: 09/30/14 End: 12/31/16 Due: 12/31/17

A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02406287 Org: User:
Start: 04/30/15 End: 04/30/16 Due: 04/30/17

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

Phase: N/A Priority: Normal
NCT ID: NCT05493111 Org: User:
Start: 11/01/22 End: 02/28/24 Due: 02/28/25

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Phase: N/A Priority: Normal
NCT ID: NCT03844945 Org: User:
Start: 03/19/19 End: 09/19/19 Due: 09/19/20

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

Phase: N/A Priority: Normal
NCT ID: NCT02874846 Org: User:
Start: 07/31/16 End: 09/30/16 Due: 09/30/17

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

Phase: N/A Priority: Normal
NCT ID: NCT05360966 Org: User:
Start: 07/18/22 End: 10/17/23 Due: 10/17/24

AR-12286 in Combination With Latanoprost

Phase: N/A Priority: Normal
NCT ID: NCT01302249 Org: User:
Start: 02/28/11 End: 12/31/11 Due: 12/31/12